Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific ...

The development of therapeutic antibodies is highly dependent on antibody engineering, whether for the generation of chimeric, humanized, Fc-engineered, bispecific, or other multispecific antibodies.

Humanization: Humanized antibodies can reduce immunogenicity, but achieving full compatibility with the human immune system can be challenging. Regulatory Hurdles ...

The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. In a phase 2, double-blind, randomized ...

The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...